Pathophysiological significance of T-type Ca2+ channels: T-type Ca2+ channels and drug development

Journal of Pharmacological Sciences

Volumn 99, Issue 3, 2005, Pages 214-220

  Tanaka, Hikaru ^a   Shigenobu, Koki ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Dihydropyridine; Efonidipine; Pacemaking; Sino atrial node; T type Ca2+ channel

Indexed keywords

CALCIUM CHANNEL T TYPE; DIHYDROPYRIDINE DERIVATIVE; EFONIDIPINE; MIBEFRADIL;

CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; ENDOCRINE SYSTEM; NERVOUS SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; RENAL PROTECTION; TACHYCARDIA;

EID: 28044471562     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FMJ05002X5     Document Type: Conference Paper

References (61)

1. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev. 2003;83:117-161.
2. 2+ channels. Neuron. 2001;31:35-45.
3. Dogrul A, Gardell LR, Ossipov MH, Tulunay FC, Lai J, Porreca F. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain. 2003;105:159-168.
4. Hagiwara N, Irisawa H, Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol. 1988;395:233-253.
5. 2+ channels in cardiac pacemaking. J Pharmacol Sci. 2005;99:197-204.
6. 2+ channels in fetal and diseased heart. J Pharmacol Sci. 2005;99:205-210.
7. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 1993;73:777-782.
8. 2+ channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol. 1999;31:1617-1625.
9. 2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res. 2000;46:442-449.
10. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res. 1994;75:149-155.
11. 2+ channels - Regulation of CACNA1H by neuronrestrictive silencer factor. J Pharmacol Sci. 2005;99:211-213.
12. 2+ channels and heart failure. Proc Assoc Am Physicians. 1999;111:429-437.
13. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation. 1999;100:2191-2197.
14. Ohashi N, Mitamura H, Tanimoto K, Fukuda Y, Kinebuchi O, Kurita Y, et al. A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling. J Cardiovasc Pharmacol. 2004;44:386-392.
15. VanBavel E, Sorop O, Andreasen D, Pfaffendorf M, Jensen BL. Role of T-type calcium channels in myogenic tone of skeletal muscle resistance arteries. Am J Physiol Heart Circ Physiol. 2002;283:H2239-H2243.
16. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res. 1996;19:31-36.
17. Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens. 2003;16:116-122.
18. 2+ channels in renal microcirculation. J Pharmacol Sci. 2005;99:221-227.
19. 2+ channel is the predominant subtype expressed in bovine and rat zona glomerulosa. Am J Physiol Cell Physiol. 2001;280:C265-C272.
20. Wagner C, Kramer BK, Hinder M, Kieninger M, Kurtz A. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. Br J Pharmacol. 1998;124:579-585.
21. Leuranguer V, Monteil A, Bourinet E, Dayanithi G, Nargeot J. T-type calcium currents in rat cardiomyocytes during postnatal development: contribution to hormone secretion. Am J Physiol Heart Circ Physiol. 2000;279:H2540-H2548.
22. Bhattacharjee A, Whitehurst RM Jr, Zhang M, Wang L, Li M. T-type calcium channels facilitate insulin secretion by enhancing general excitability in the insulin-secreting beta-cell line, INS-1. Endocrinology. 1997;138:3735-3740.
23. 2+ channels. Jpn J Pharmacol. 2001;85:339-350.
24. Van der Vring JA, Cleophas TJ, Van der Wall EE, Niemeyer MG. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. Am J Ther. 1999;6:229-233.
25. Clozel JP, Ertel EA, Ertel SI. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens. 1997;Suppl 15:S17-S25.
26. Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, et al. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)- 6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther. 2004;309:193-199.
27. Sidach SS, Mintz IM. Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels. J Neurosci. 2002;22:2023-2034.
28. Masuda Y, Tanaka S. Efonidipine hydrochloride: a new calcium antagonist. Cardiovasc Drug Rev. 1994;12:123-135.
29. 2+ channel antagonists on sinus node: prolongation of late phase 4 depolarization by efonidipine. Eur J Pharmacol. 1997;335:15-21.
30. 2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol. 1998;349:351-357.
31. Shudo C, Masuda Y, Sakai T, Tanaka S, Shigenobu K, Kasuya Y. Studies on the hypotensive mechanisms of NZ-105, a new dihydropyridine derivative, in rats and rabbits. Gen Pharmacol. 1993;24:411-418.
32. Yokoyama T, Ichihara K, Abiko T. Effect of efonidipine, a novel dihydropyridine derivative, on myocardial metabolic changes induced by coronary artery ligation in dogs: comparison with nifedipine. Fundam Clin Pharmacol. 1997;11:245-251.
33. Yamada K, Hosoda S, Kishida H, Taniguchi K, Nakashima M, Origasa H, et al. Clinical evaluation of efonidipine hydrochloride (NZ-105) on exercise tolerance in patients with angina pectoris. Kiso to Rinsho. 1996;30:3433-3464.
34. Saito T, Fujii K, Takizawa T, Toyosaki T, Kuwabara Y, Kobayashi S, et al. Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina. Arzneimittelforschung. 1996;46:861-867.
35. Fujikura N, Yokoyama T, Masuda Y, Shikada K, Tanaka S. Effect of efonidipine hydrochloride on myocardial oxygen balance in anesthetized dogs. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 1996;108:39-48. (text in Japanese with English abstract)
36. Fujikura N, Yokoyama T, Masuda Y, Shikada K, Tanaka S. Effect of efonidipine hydrochloride (NZ-105), a dihydropyridine derivative with calcium antagonistic action, on myocardial oxygen tension in anesthetized dogs. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 1996;108:267-274. (text in Japanese with English abstract)
37. Yokoyama T, Fujikura N, Masuda Y, Shikada K, Tanaka S. Effects of efonidipine hydrochloride, a calcium antagonist derived from dihydropyridine, on acute myocardial ischemia in anesthetized open-chest dogs. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 1996;108: 307-321. (text in Japanese with English abstract)
38. Masuda Y, Iwama T, Yamashita T, Sakai T, Hibi M, Tanaka S, et al. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro. Arch Int Pharmacodyn Ther. 1991;314:57-73.
39. Tanaka H, Masumiya H, Sekine T, Shijuku T, Sugahara M, Taniguchi H, et al. Myocardial and vascular effects of efonidipine in vitro as compared with nifedipine, verapamil and diltiazem. Gen Pharmacol. 1996;27:451-454.
40. 2+ channel antagonist, on sino-atrial node and ventricular myocardia. Res Commun Mol Pathol Pharmacol. 1999;104:321-329.
41. Ono K, Iijima T. Analysis of the negative chronotropic action of efonidipine in rabbit sinoatrial node cells. Jpn J Pharmacol. 2001;85 Suppl II:145P.
42. Demir SS, Clark JW, Murphey CR, Giles WR. A mathematical model of a rabbit sinoatrial node cell. Am J Physiol. 1994;266:C832-C852.
43. Ono K, Lee T, Kaku T, Arita M. Pharmacological properties of the human cloned T-type calcium channel. Jpn J Electrocardiol. 2000;20 Suppl 3:109-112.
44. 2+ channel blocking action, on heart rate. Ther Res. 2001;22:883-889.
45. 2+ current by efonidipine in cardiomyocytes. Life Sci. 2000;68:345-351.
46. 2+ transients in rat atrial and ventricular cardiomyocytes. Bioimages. 2001;9:87-93.
47. 2+ release units. J Pharmacol Sci. 2003;93:248-252.
48. 2+ release from the sarcoplasmic reticulum in guinea-pig ventricular myocytes. J Physiol. 1998;508:439-451.
49. Honda M, Hayashi K, Matsuda H, Kubota E, Tokuyama H, Okubo K, et al. Divergent renal vasodilator action of L- and Ttype calcium antagonists in vivo. Hypertension. 2001;19:2031-2037.
50. Yaoita H, Arima S, Omata K, Ito S. Effects of efonidipine hydrochloride on the glomerular hemodynamics. Jpn Pharmacol Ther. 1999;27:1589-1596.
51. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney. Hypertension. 2001;38:343-347.
52. Shudo C, Masuda Y, Sugita H, Tamura T, Furukawa S, Hayashi K, et al. Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats. Arzneimittelforschung. 1996;46:852-854.
53. Masuda Y, Miyajima M, Shudo C, Tanaka S, Shigenobu K, Kasuya Y. Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues. Gen Pharmacol. 1995;26:339-345.
54. Masumiya H, Matsuda T, Tanaka Y, Tanaka H, Shigenobu K. Possible requirement of phosphonate moiety for efonidipine effects on the sino-atrial node action potential. Life Sci. 2000;66:PL239-PL244.
55. 2+ channels distributed in cardiovascular system. Int J Mol Med. 1999;3:455-466.
56. Takeda K, Yamagishi R, Masumiya H, Tanaka H, Shigenobu K. Effect of cilnidipine on L- and T-type calcium currents in guinea pig ventricle and action potential in rabbit sinoatrial node. J Pharmacol Sci. 2004;95:398-401.
57. 2+ channels in smooth muscle. Eur J Pharmacol. 1994;252:267-274.
58. 2+ antagonist. Pharmacology. 2000;61:57-61.
59. Inotsume N, Nakano M. Stereoselective determination and pharmacokinetics of dihydropyridines: an updated review. J Biochem Biophys Methods. 2002;54:255-274.
60. 2+ channels. Br J Pharmacol. 2004;143:1050-1057.
61. Tanaka H, Komikado C, Shimada H, Takeda K, Namekata I, Kawanishi T, et al. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J Pharmacol Sci. 2004;96:499-501.